FUTURE OF FERTILITY
Today, the fertility market is changing fast,
and the importance of technologies becomes
more and more evident. There is a growing
need for further innovation, and Merck
aspires to continue to be the leader in pro-
viding treatments, technologies and services
to help fertility specialists and couples in
Malaysia increase the chances of bringing a
newborn home.
Hamann stressed the benefit of new
technologies is to increase efficiency and
consistency in IVF laboratories. “By entering
the field of fertility technologies, Merck seeks
to support couples on their fertility journey
in every way we can. As the steps taken in the
laboratory play a critical role in increasing
treatment success rates, innovative technol-
ogies can make a real difference. We combine
our existing drug portfolio with a continu-
ously expanding range of technologies that
aims to improve standardisation, automation
and excellence in Assisted Reproductive
Treatment (ART).
Merck celebrates 350 years
of innovation
“ALWAYS CURIOUS - IMAGINE
THE NEXT 350 YEARS’ is the
theme of Merck’s 350th anniversary
celebration this year. Chris Hamann,
Merck Malaysia’s President and Chief
Executive Officer commented that to
continue operations for a further 350
years, Merck needs to be constantly
innovating.
“We started off as a small
family-run pharmacy in Darmstadt,
Germany. Through innovation we
have grown to approximately 52,000
employees providing solutions and
technologies in over 66 countries.
So, this theme aptly symbolises
the spirit of the company over
“Please come
forward, and as
early as possible
to seek medical
advice from
fertility specialists.
Remember, you are
not alone in this
journey,”
- Chris Hamann
the last 350 years in terms of how
we’ve evolved, to be able to provide
healthcare, life sciences and chemical
solutions for healthcare partners as
well as patients across the globe,” he
shared.
With more than 6,500 research and
development professionals worldwide,
Merck is dedicated to developing
pioneering solutions and technologies,
such as genome editing and deep data
analysis, in addition to accelerating
and improving drug development and
biomedical technologies, leading to
innovations such as sensor systems
and highly efficient microchips for the
next generation of technical devices.
11
Hamann said patient awareness is the
biggest challenge to deal with in treating
infertility. The general public is still uncom-
fortable to come forward to seek treatment
or to even talk about their infertility issues.
One of Merck’s recent initiatives, www.
fertility.com, is designed to help couples
to understand existing options regarding
infertility treatments as well as obtain advice
and support.
“Furthermore, www.fertility.com allows
couples who are going through fertility issues
to understand the causes of infertility for both
men and women, how age affects fertility
and the various fertility examination options
available,” Hamann explained.
Merck hopes to continue educating the
public on addressing their challenges, while
also further encouraging them to seek advice
from fertility specialists to deal with the emo-
tional aspect which accompanies infertility.
Xtra